Causes of Mild AST and ALT Elevation
The most common causes of mild AST and ALT elevation (less than 5 times the upper limit of normal) are non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease, followed by viral hepatitis (hepatitis B and C), drug-induced liver injury, and hereditary hemochromatosis 1.
Primary Hepatic Causes
Most Common (Prevalence-Based Approach)
The evaluation should prioritize diseases based on their prevalence in primary care, where approximately 10% of the U.S. population has elevated transaminase levels 1:
- Non-alcoholic fatty liver disease (NAFLD): The leading cause, particularly in patients with metabolic syndrome risk factors (obesity, type 2 diabetes, hypertension, dyslipidemia) 2, 1
- Alcoholic liver disease: Second most common cause 1
- Viral hepatitis: Hepatitis B and C can present with only mild transaminase elevations or even normal ALT levels, yet carry substantial risk of progression to end-stage liver disease if undiagnosed 2, 1
- Drug-induced liver injury: Including prescription medications, over-the-counter drugs, vitamins, and herbal supplements 3, 1
Uncommon Causes
- Hereditary hemochromatosis 1
- Autoimmune hepatitis 2, 1
- Alpha-1 antitrypsin deficiency 1
- Wilson disease 1
Extrahepatic Causes
Critical caveat: AST is present in cardiac muscle, skeletal muscle, and erythrocytes, making ALT the more specific marker for liver damage 4. Extrahepatic sources include:
- Thyroid disorders 1
- Celiac disease 1
- Hemolysis 4
- Muscle disorders (particularly relevant when AST is disproportionately elevated compared to ALT) 4
- Myocardial infarction 4
Special Consideration: Macro-AST
An important and often overlooked benign cause of isolated AST elevation is macro-AST, where AST forms a complex with immunoglobulins 5, 6, 7. This can lead to unnecessary invasive testing including liver biopsies. Suspect macro-AST when:
- Isolated AST elevation persists without other abnormalities
- ALT and creatine kinase are normal (excluding liver and muscle disease)
- Patient remains asymptomatic for extended periods 5, 6, 7
Critical Clinical Context Issues
The Magnitude Paradox
A crucial pitfall: The degree of transaminase elevation does NOT correlate with prognosis or disease severity 2. For example:
- Acute hepatitis A can cause ALT >1000 U/L but has excellent prognosis
- Chronic hepatitis C may have normal-range ALT yet progress to end-stage liver disease over 10 years 2
- NAFLD, alcoholic liver disease, and hepatitis C—the most common causes of chronic liver disease—frequently present with only mild elevations 2
Reference Range Limitations
The current upper limit of normal for ALT may be too high due to inclusion of patients with occult NAFLD in reference populations 2. Hepatitis B treatment guidelines recognize ALT >30 U/L as significant in males and >19 U/L in females 2. Many patients with significant liver fibrosis have transaminases within the "normal" reference range 2.
Initial Diagnostic Approach
Based on established guidelines 3, 1, the initial evaluation should include:
Metabolic assessment:
- Waist circumference, blood pressure
- Fasting lipid panel
- Fasting glucose or HbA1C
Laboratory testing:
- Complete blood count with platelets
- Serum albumin (synthetic function)
- Hepatitis C antibody
- Hepatitis B surface antigen
- Iron studies (serum iron, total iron-binding capacity, ferritin)
Clinical history specifics:
- Detailed medication inventory (prescription, over-the-counter, vitamins, herbs, supplements) 3
- Alcohol consumption quantification
- Risk factors for viral hepatitis (injection drug use, country of origin, parental exposure, incarceration) 2
- Review of previous liver test results 2
Management Algorithm
If initial testing suggests NAFLD and is otherwise unremarkable: Trial of lifestyle modification is appropriate 1.
If elevation persists: Obtain hepatic ultrasonography and test for uncommon causes 1.
If more significant elevations, abnormal albumin/prothrombin time, or evidence of chronic liver disease/hepatic decompensation: More expeditious and complete evaluation is warranted 3.
For chronic elevations (≥6 months): Additional serologic and radiologic evaluations, potentially including liver biopsy 3.